# Submitting Next Generation Sequencing Data to the Division of Antiviral Products Guidance for Industry Technical Specifications Document - FDA Guidance Document Source: https://www.globalkeysolutions.net/guidances/guidance-document/submitting-next-generation-sequencing-data-to-the-division-of-antiviral-products-guidance-for-industry-technical-specifications-document/4edd1e8a-43c4-4293-b6b8-ac9472e1a619 > FDA guidance document: Submitting Next Generation Sequencing Data to the Division of Antiviral Products Guidance for Industry Technical Specifications Document. Issue date: July 18, 2019. Get complete insights and analysis. --- ## Details - Title: Submitting Next Generation Sequencing Data to the Division of Antiviral Products Guidance for Industry Technical Specifications Document - Communication Type: Guidance Document - Product Type: devices - Office Name: Center for Drug Evaluation and Research - Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c - Issue Date: 2019-07-18 - Last Changed: 2020-05-05 - Docket Number: FDA-2017-D-6821 ## Related Documents - [Submitting Clinical Trial Datasets and Documentation for Clinical Outcome Assessments Using Item Response Theory](https://www.globalkeysolutions.net/guidances/guidance-document/submitting-clinical-trial-datasets-and-documentation-for-clinical-outcome-assessments-using-item-response-theory/9895a301-585a-4b74-83a1-3b526f3ec3d3) - [Submitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies of Pharmaceuticals](https://www.globalkeysolutions.net/guidances/guidance-document/submitting-nonclinical-datasets-for-evaluation-of-rodent-carcinogenicity-studies-of-pharmaceuticals/5558f50a-6637-45c7-9848-23f5e55738d6) - [Submitting Patient-Reported Outcome Data in Cancer Clinical Trials](https://www.globalkeysolutions.net/guidances/guidance-document/submitting-patient-reported-outcome-data-in-cancer-clinical-trials/cdd19350-5c19-44b6-9812-51398fa0fc71)